The sequence type 131 (ST131)-H30 clone is responsible for a significant proportion of multidrug-resistant extraintestinal Escherichia coli infections. Recently, the C1-M27 clade of ST131-H30, associated with bla CTX-M-27 , has emerged. The complete genome sequence of E. coli isolate 81009 belonging to this clone, previously used during the development of ST131-specific monoclonal antibodies, is reported here.
81009 was supported by an array of virulence determinants identified in silico (12) , including those involved in adhesion (upaB, crl, csgA, fimH, and iha), biofilm formation (bscA, agn43, and F9 fimbriae), survival in body fluids (iss and gad), and toxin production (senB and sat). E. coli 81009 was also shown to carry the H30 allele of the fimH gene. Additionally, an 11.8-kb region (M27PP1) specific to the C1-M27 clade of the H30 subclone (4) was identified, confirming that strain 81009 belongs to the C1-M27 clade.
Plasmid pEC-81009 was found to belong to the IncFII-FIA-FIB group by in silico replicon typing (10) . Among the 160 predicted genes carried on this plasmid, toxin/ antitoxin systems (Phd/Doc, CcdBA, and Kid/Kis) and genes encoding resistance to aminoglycosides (aadA5, strA, and strB), sulfonamide (sul1 and sul2), tetracycline [tet(A)], macrolides (mphA), trimethoprim (dfrA17), and the extended-spectrum ␤-lactamase (ESBL) gene bla CTX-M-27 were identified.
The availability of E. coli 81009 in a public repository and its well-characterized phenotype and genotype make it a suitable model organism for studying the ST131 C1-M27 clade.
Accession number(s).
The complete sequences of the chromosome and plasmid of E. coli 81009 have been deposited in GenBank under accession numbers CP021179 and CP021180, respectively.
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